Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
101.59(c)
104.7(c)
103.23(c)
105.43(c)
108.44(c)
Last
3 151 568
2 018 242
1 615 666
2 256 344
1 690 445
Volume
-4.02% +3.06% -1.40% +2.13% +2.85% Change
Sales 2020
497 M 605 M 605 M
Net income 2020
-329 M -401 M -401 M
Net cash position 2020
936 M 1 139 M 1 139 M
P/E ratio 2020
-72,0x
Yield 2020
-
Sales 2021
6 507 M 7 918 M 7 918 M
Net income 2021
4 445 M 5 409 M 5 409 M
Net cash position 2021
4 339 M 5 281 M 5 281 M
P/E ratio 2021
5,77x
Yield 2021
-
Capitalization
21 455 M 26 111 M 26 108 M
EV / Sales 2020
41,3x
EV / Sales 2021
2,63x
Nbr of Employees
1 800
Free-Float
92,4%
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer...
Notations Surperformance© of BioNTech SE
Trading Rating : Investor Rating :
All news about BIONTECH SE
News in other languages on BIONTECH SE
Analyst Recommendations on BIONTECH SE
CureVac strikes COVID-19 vaccine alliance with Bayer
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BIONTECH SE
Short Term Mid-Term Long Term Trends Neutral Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
10
Average target price
92,65 €
Last Close Price
89,10 €
Spread / Highest target
24,7%
Spread / Average Target
3,98%
Spread / Lowest Target
-35,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
